Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-25

FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for ambrisentan from Mylan Pharmaceuticals Inc., signaling regulatory approval related to this generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)